We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Study Evaluates Molecular Diagnostics Tests for SARS-CoV-2

By LabMedica International staff writers
Posted on 04 Jun 2020
The explosion of COVID-19 cases in the USA has highlighted the critical role diagnostic testing plays in medical and public health decision making in containing and mitigating the SARS-CoV-2 pandemic.

Reverse transcription polymerase chain reaction (RT-PCR) is the mainstay of SARS-CoV-2 detection in vitro. More...
The authorized assays for SARS-CoV-2 have mostly targeted two loci of the coronavirus. Conducting head-to-head evaluations of technologies is one of the best ways to know how well tests work. In a crisis, though, these evaluations must sometimes take a back seat to patient care. Almost four months into the COVID-19 outbreak, test comparisons are now popping up at a rapid pace and positive sense, single-stranded RNA virus by real time RT-PCR and are reported qualitatively.

Medical Laboratory Scientists at the University of Washington Medical Center (Seattle, WA, USA) collected 169 nasopharyngeal (NP) swabs from patient specimens submitted to the University of Washington Medical Center laboratories for clinical diagnostic testing. The team compared the analytical performance of a laboratory developed test (LDT) developed in their clinical laboratory based on CDC primer sets and four commercially available, FDA emergency use authorized assays for SARS-CoV-2. These were: the Xpert Xpress SARS-CoV-2, (Cepheid, Sunnyvale, CA, USA); the Simplexa COVID-19 Direct Kit (DiaSorin Molecular, Cypress, CA, USA); the Panther Fusion SARS-CoV-2 test (Hologic, Bedford, MA, USA); and the cobas SARS-CoV-2 Test (Roche Diagnostics, Risch-Rotkreuz, Switzerland).

The scientists reported that the LDT and Cepheid Xpert Xpress SARS-CoV-2 assays were the most sensitive assays for SARS-CoV-2 with 100% agreement across specimens. The Hologic Panther Fusion, DiaSorin Simplexa, and Roche Cobas 6800 only failed to detect positive specimens near the limit of detection of the CDC-based LDT assay. The in-house LDT demonstrated 100% concordance with the Cepheid Xpert Xpress, also detecting the extremely low viral load specimen as an inconclusive.

The authors concluded that all the assays were 100% specific, using the CDC-based LDT as the gold standard. The results provided initial test performance characteristics for SARS-CoV-2 RT-PCR and highlight the importance of having multiple viral detection testing platforms available in a public health emergency. The study was published on April 29, 2020 in the Journal of Clinical Microbiology.



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.